Your session is about to expire
← Back to Search
Hormone Therapy
Bevacizumab + Hormone & Radiation Therapies for Prostate Cancer
Phase 2
Waitlist Available
Research Sponsored by Virginia Mason Hospital/Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
High-risk, locally advanced disease meeting specific criteria (Gleason score 8-10, or Prostate-specific antigen > 20 ng/dL AND Gleason score 7, or T2a disease with specific biopsy requirements)
Histologically confirmed adenocarcinoma of the prostate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying bevacizumab in combination with hormone therapy and radiation therapy to see how well it works in treating patients with high-risk locally advanced prostate cancer.
Who is the study for?
Men with high-risk, locally advanced prostate cancer can join this trial. They should have a PSA >20 ng/dL, Gleason score of 7-10, and no metastatic disease. Participants need to be relatively healthy (ECOG 0-2), with adequate blood counts and organ function, controlled blood pressure, no recent heart attacks or strokes, and not on prior hormone therapy for prostate cancer.Check my eligibility
What is being tested?
The study is testing the combination of Bevacizumab (a monoclonal antibody that blocks tumor growth), hormone therapy (drugs like goserelin and bicalutamide that stop production of male hormones), and radiation therapy to see if they work better together in treating patients with aggressive prostate cancer.See study design
What are the potential side effects?
Bevacizumab may cause issues like high blood pressure, bleeding or clotting problems, headaches or vision changes due to brain swelling. Hormone therapy might lead to hot flashes, sexual dysfunction or bone thinning. Radiation could result in skin irritation at the treatment site or fatigue.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My prostate cancer is high-risk with specific Gleason scores or PSA levels.
Select...
My prostate cancer diagnosis was confirmed through a tissue examination.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy
Safety
Find a Location
Who is running the clinical trial?
Virginia Mason Hospital/Medical CenterLead Sponsor
20 Previous Clinical Trials
3,408 Total Patients Enrolled
2 Trials studying Prostate Cancer
317 Patients Enrolled for Prostate Cancer
Jacqueline Vuky, MDStudy ChairVirginia Mason Hospital/Medical Center
3 Previous Clinical Trials
53 Total Patients Enrolled
3 Trials studying Prostate Cancer
53 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had major surgery in the last 4 weeks.I have received treatments like chemotherapy for prostate cancer.My prostate cancer is high-risk with specific Gleason scores or PSA levels.I have taken hormone therapy for prostate cancer, not including finasteride.I have not had a heart attack or stroke in the last 6 months.My prostate cancer diagnosis was confirmed through a tissue examination.My recent exams show no signs of cancer spread.I can take care of myself and am up and about more than half of my waking hours.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the FDA granted authorization for this treatment?
"Our team at Power assigned this new treatment a safety rating of 2, which reflects the limited amount of data that has been collected in Phase 2 trials with regards to its efficacy."
Answered by AI
Is this study actively seeking volunteers at present?
"This trial has already reached its maximum number of participants, as evidenced by the last update to clinicaltrials.gov on November 5th 2013; however there are 1321 other medical studies currently recruiting patients at this time."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger